ALL Panel (Cytogenetics + FISH [BCR/ABL, TEL/AML1, MLL, E2A]) in UAE – 2800 AED

Executive Summary & Core Metrics

Clinical Authority & Patient Trust: 99.9% diagnostic sensitivity achieved through ISO 9001:2015‑certified processing (Cert: INT/EGQ/2509DA/3139). Hospital extraction only – sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety. Post‑test telephonic guidance by Consultant Medical Genetics. Direct insurance billing verification via WhatsApp: +971 54 548 8731.

Core Metrics: Fixed price of 2800 AED, turnaround time of 10 working days, DHA‑compliant protocols, and stringent quality controls ensure accurate risk stratification for acute lymphoblastic leukemia.

Test Overview & Methodology

The ALL Panel (Cytogenetics + FISH) integrates conventional karyotyping and targeted fluorescence in‑situ hybridization to detect the most clinically significant gene fusions in acute lymphoblastic leukemia. In the UAE, this panel delivers definitive risk stratification and therapy‑guiding insights, reported within 10 days, at a fixed price of 2800 AED under DHA‑compliant protocols.

The combination of G‑banding karyotyping and multiplex FISH probes covering BCR/ABL, TEL/AML1, MLL, and E2A rearrangements ensures comprehensive detection of both balanced and cryptic chromosomal abnormalities essential for treatment planning.

Parameter	Our ALL Panel	Closest Alternative (Conventional Karyotyping Alone)
Methodology	G‑banding Karyotyping + Multi‑probe FISH (BCR/ABL, TEL/AML1, MLL, E2A)	G‑banding Karyotyping only
Detection Rate	99.9% for targeted abnormalities; uncovers cryptic rearrangements invisible to karyotyping	~60–70% for gross chromosomal changes; misses clinically actionable cryptic fusions
Turnaround Time	10 working days (optimized culture + FISH workflow)	14–21 days
Clinical Utility	Comprehensive risk stratification, MRD surrogate, targeted therapy eligibility (e.g., TKI for BCR/ABL)	Basic ploidy‑based risk classification only; misses key driver fusions

Physician Insight & Safety Protocols

“As a Consultant in Medical Genetics, I recognise the profound emotional impact of a leukemia diagnosis on patients and their families. This panel’s precision – combining cytogenetics with targeted FISH – allows us to pinpoint critical genetic drivers, enabling your oncologist to design the most personalised and effective treatment strategy. However, these results must always be interpreted within the full clinical context and never in isolation.”

— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403

Advisory: Medication Continuation

⚠️ Do not discontinue or modify any prescribed medication without direct instruction from your treating physician.

Exclusion Criteria & Red Flags

Patients with acute, uncontrolled bleeding disorders or severe thrombocytopenia (platelets <20×10⁹/L) may require medical optimisation before bone marrow aspiration.
Severe local infection at the intended sampling site is an absolute contraindication for elective marrow aspiration.
Seek immediate emergency care if you experience sudden high fever (>38.5°C), uncontrolled bleeding, rapid swelling of lymph nodes, or severe bone pain unrelieved by rest.

Patient FAQ & Clinical Guidance

1. What does the ALL Panel with FISH detect, and why is it ordered?

This comprehensive genetic test directly identifies chromosomal abnormalities and gene fusions—BCR/ABL, TEL/AML1, MLL, and E2A rearrangements—that define high‑risk acute lymphoblastic leukemia subtypes and guide targeted therapies.

2. How should I prepare for the sample collection, and is it painful?

Sample collection is performed in an accredited hospital facility. Bone marrow aspiration is conducted under local anaesthesia; you may feel mild pressure but discomfort is controlled. Peripheral blood collection, if also required, is a simple venipuncture. No home collection is available for this test.

3. When will I receive the results and who will explain them?

The full cytogenetics and FISH report is available within 10 working days. A consultant medical geneticist will provide a dedicated telephonic explanation of your results, linking the findings to your treatment plan.

UAE Regulatory & Data Privacy Adherence

All genetic and health data processed by this laboratory is handled in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent abide by Federal Decree-Law No. 4 of 2016 on Medical Liability.

Your information is encrypted and stored exclusively on UAE‑licensed servers under the highest confidentiality standards. All reporting is DHA‑regulated and ISO 9001:2015 certified (Cert: INT/EGQ/2509DA/3139).

Clinical & Logistical Metadata

Test Name	ALL Panel (Cytogenetics + FISH [BCR/ABL, TEL/AML1, MLL, E2A])
Price (AED)	2,800 AED
Turnaround Time	10 working days
Sample Type / Matrix	Bone marrow aspirate (hospital extraction only) or peripheral blood (if clinically indicated)
Methodology Used	G‑banding Karyotyping + Multi‑probe FISH (BCR/ABL, TEL/AML1, MLL, E2A)
ICD-10-CM Code	C91.00 (Acute lymphoblastic leukemia, unspecified)
LOINC Code	53780-4 (Cytogenetics panel - Bone marrow)
DHA Facility License & Laboratory Address	License No. 1143 – DNA Labs UAE, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE